← Leaderboards
Antonino None Catanzaro
University Of California San Diego
$18,895,790
Attributed
$22,108,878
Total exposure
13
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–23$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$22,108,878 · 13
By mechanism
U01$10,877,063 · 1
R01$9,747,366 · 3
N01$787,728 · 1
R43$596,721 · 1
K07$100,000 · 1
M01$0 · 6
Top collaborators
- Timothy Charles Rodwell8 shared
- Patrick Sislian2 shared
Most similar at University Of California San Diego
Same institution · by research overlap
- Terry L Jernigan$37,204,806
- Cheryl L Rock$9,282,089
- Dennis A Carson$36,140,483
- Sadik Esener$6,471,536
Others in their field
Top investigators on “Tuberculosis”
- Judith S. Currier · University Of California Los Angeles$301,722,065
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$297,204,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$267,912,117
- Lawrence Corey · Fred Hutchinson Cancer Center$255,939,398
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$200,192,298
- Sharon A Nachman · Johns Hopkins University$194,852,226
Research focus
TuberculosisHuman SubjectClinical ResearchHuman Therapy EvaluationDrug Screening /EvaluationEnrollmentIsoniazidPerformanceMycobacterium TuberculosisBaseDetectionMoldovaMicroorganism Disease ChemotherapySensitivity And SpecificitySputumAntigensSamplingBloodCharacteristicsChildMycobacterialRespiratory Disorder ChemotherapyAntimicroorganism AntibodyCohort
Grant awards (77)
An Antigen-Detection Blood Test for Pulmonary Tuberculosis$728,243
R01 · FY2023 · AI · contact PI
Identifying individuals at risk of progression to active tuberculosis$742,137
R01 · FY2022 · AI · contact PI
An Antigen-Detection Blood Test for Pulmonary Tuberculosis$736,330
R01 · FY2022 · AI · contact PI
An Antigen-Detection Blood Test for Pulmonary Tuberculosis$736,404
R01 · FY2021 · AI · contact PI
Identifying individuals at risk of progression to active tuberculosis$728,879
R01 · FY2021 · AI · contact PI
Identifying individuals at risk of progression to active tuberculosis$711,592
R01 · FY2020 · AI · contact PI
An Antigen-Detection Blood Test for Pulmonary Tuberculosis$694,190
R01 · FY2020 · AI · contact PI
An Antigen-Detection Blood Test for Pulmonary Tuberculosis$751,680
R01 · FY2019 · AI · contact PI
Identifying individuals at risk of progression to active tuberculosis$715,056
R01 · FY2019 · AI · contact PI
Identifying individuals at risk of progression to active tuberculosis$798,023
R01 · FY2018 · AI · contact PI
Rapid Tests for Drug Resistance to Detect Extensively Drug-Resistant Tuberculosis$1,430,463
U01 · FY2013 · AI · contact PI
Cough collection as a replacement for sputum samples for diagnosing Tuberculosis$296,721
R43 · FY2013 · AI
Rapid Tests for Drug Resistance to Detect Extensively Drug-Resistant Tuberculosis$2,312,751
U01 · FY2012 · AI · contact PI
Cough collection as a replacement for sputum samples for diagnosing Tuberculosis$300,000
R43 · FY2012 · AI
Rapid Tests for Drug Resistance to Detect Extensively Drug-Resistant Tuberculosis$2,342,929
U01 · FY2011 · AI · contact PI
Rapid Tests for Drug Resistance to Detect Extensively Drug-Resistant Tuberculosis$2,312,396
U01 · FY2010 · AI · contact PI
Rapid Tests for Drug Resistance to Detect Extensively Drug-Resistant Tuberculosis$2,478,524
U01 · FY2009 · AI · contact PI
National Tuberculosis Curriculum Consortium (NTCC)$787,728
N01 · FY2009 · HL · contact PI
Clinical Suspicion of TB: A Technology Assessment Tool$150,001
R01 · FY2007 · AI · contact PI
Clinical Suspicion of TB: A Technology Assessment Tool$644,351
R01 · FY2006 · AI · contact PI
Clinical Suspicion of TB: A Technology Assessment Tool$609,640
R01 · FY2005 · AI
Clinical Suspicion of TB: A Technology Assessment Tool$647,226
R01 · FY2004 · AI
Clinical Suspicion of TB: A Technology Assessment Tool$353,614
R01 · FY2003 · AI
TREATMENT OF HIV RELATED TUBERCULOSIS USING A RIFABUTIN BASED REGIMEN$0
M01 · FY2002 · RR
RIFAPENTINE AND INH COMPARED TO TWICE WEEKLY RIFAMPIN AND INH$0
M01 · FY2002 · RR
RIFAPENTINE AND INH COMPARED TO TWICE WEEKLY RIFAMPIN AND INH$0
M01 · FY2002 · RR
RIFAPENTINE AND INH COMPARED TO TWICE WEEKLY RIFAMPIN AND INH$0
M01 · FY2002 · RR
RIFAPENTINE AND INH COMPARED TO TWICE WEEKLY RIFAMPIN AND INH$0
M01 · FY2002 · RR
SCH56592 IN CHRONIC ACTIVE PULMONARY OR NON MENINGEAL COCCI$0
M01 · FY2002 · RR
SCH56592 IN CHRONIC ACTIVE PULMONARY OR NON MENINGEAL COCCI$0
M01 · FY2002 · RR
SCH56592 IN CHRONIC ACTIVE PULMONARY OR NON MENINGEAL COCCI$0
M01 · FY2002 · RR
SCH56592 IN CHRONIC ACTIVE PULMONARY OR NON MENINGEAL COCCI$0
M01 · FY2002 · RR
ITRACONAZOLE IN CYCLODEXTRIN VS PLACEBO IN ASPERGILLOMA$0
M01 · FY2002 · RR
ITRACONAZOLE IN CYCLODEXTRIN VS PLACEBO IN ASPERGILLOMA$0
M01 · FY2002 · RR
ITRACONAZOLE IN CYCLODEXTRIN VS PLACEBO IN ASPERGILLOMA$0
M01 · FY2002 · RR
ITRACONAZOLE IN CYCLODEXTRIN VS PLACEBO IN ASPERGILLOMA$0
M01 · FY2002 · RR
TREATMENT OF HIV RELATED TUBERCULOSIS USING RIFABUTIN$0
M01 · FY2002 · RR
TREATMENT OF HIV RELATED TUBERCULOSIS USING RIFABUTIN$0
M01 · FY2002 · RR
TREATMENT OF HIV RELATED TUBERCULOSIS USING RIFABUTIN$0
M01 · FY2002 · RR
TREATMENT OF HIV RELATED TUBERCULOSIS USING RIFABUTIN$0
M01 · FY2002 · RR
TREATMENT OF HIV RELATED TUBERCULOSIS USING A RIFABUTIN BASED REGIMEN$0
M01 · FY2002 · RR
TREATMENT OF HIV RELATED TUBERCULOSIS USING A RIFABUTIN BASED REGIMEN$0
M01 · FY2002 · RR
TREATMENT OF HIV RELATED TUBERCULOSIS USING A RIFABUTIN BASED REGIMEN$0
M01 · FY2002 · RR
INHALED CYTOKINES FOR MYCOBACTERIAL LUNG DISEASE$0
M01 · FY2002 · RR
INHALED CYTOKINES FOR MYCOBACTERIAL LUNG DISEASE$0
M01 · FY2002 · RR
INHALED CYTOKINES FOR MYCOBACTERIAL LUNG DISEASE$0
M01 · FY2002 · RR
INHALED CYTOKINES FOR MYCOBACTERIAL LUNG DISEASE$0
M01 · FY2002 · RR
INHALED CYTOKINES FOR MYCOBACTERIAL LUNG DISEASE$0
M01 · FY2001 · RR
RIFAPENTINE AND INH COMPARED TO TWICE WEEKLY RIFAMPIN AND INH$0
M01 · FY2001 · RR
RIFAPENTINE AND INH COMPARED TO TWICE WEEKLY RIFAMPIN AND INH$0
M01 · FY2001 · RR
SCH56592 IN CHRONIC ACTIVE PULMONARY OR NON MENINGEAL COCCI$0
M01 · FY2001 · RR
SCH56592 IN CHRONIC ACTIVE PULMONARY OR NON MENINGEAL COCCI$0
M01 · FY2001 · RR
ITRACONAZOLE IN CYCLODEXTRIN VS PLACEBO IN ASPERGILLOMA$0
M01 · FY2001 · RR
ITRACONAZOLE IN CYCLODEXTRIN VS PLACEBO IN ASPERGILLOMA$0
M01 · FY2001 · RR
TREATMENT OF HIV RELATED TUBERCULOSIS USING RIFABUTIN$0
M01 · FY2001 · RR
TREATMENT OF HIV RELATED TUBERCULOSIS USING RIFABUTIN$0
M01 · FY2001 · RR
TREATMENT OF HIV RELATED TUBERCULOSIS USING A RIFABUTIN BASED REGIMEN$0
M01 · FY2001 · RR
TREATMENT OF HIV RELATED TUBERCULOSIS USING A RIFABUTIN BASED REGIMEN$0
M01 · FY2001 · RR
INHALED CYTOKINES FOR MYCOBACTERIAL LUNG DISEASE$0
M01 · FY2001 · RR
TUBERCULOSIS$100,000
K07 · FY2000 · HL
RIFAPENTINE AND INH COMPARED TO TWICE WEEKLY RIFAMPIN AND INH$0
M01 · FY2000 · RR
RIFAPENTINE AND INH COMPARED TO TWICE WEEKLY RIFAMPIN AND INH$0
M01 · FY2000 · RR
RIFAPENTINE AND INH COMPARED TO TWICE WEEKLY RIFAMPIN AND INH$0
M01 · FY2000 · RR
SCH56592 IN CHRONIC ACTIVE PULMONARY OR NON MENINGEAL COCCI$0
M01 · FY2000 · RR
SCH56592 IN CHRONIC ACTIVE PULMONARY OR NON MENINGEAL COCCI$0
M01 · FY2000 · RR
SCH56592 IN CHRONIC ACTIVE PULMONARY OR NON MENINGEAL COCCI$0
M01 · FY2000 · RR
INHALED CYTOKINES FOR MYCOBACTERIAL LUNG DISEASE$0
M01 · FY2000 · RR
INHALED CYTOKINES FOR MYCOBACTERIAL LUNG DISEASE$0
M01 · FY2000 · RR
TREATMENT OF HIV RELATED TUBERCULOSIS USING A RIFABUTIN BASED REGIMEN$0
M01 · FY2000 · RR
TREATMENT OF HIV RELATED TUBERCULOSIS USING A RIFABUTIN BASED REGIMEN$0
M01 · FY2000 · RR
TREATMENT OF HIV RELATED TUBERCULOSIS USING A RIFABUTIN BASED REGIMEN$0
M01 · FY2000 · RR
TREATMENT OF HIV RELATED TUBERCULOSIS USING RIFABUTIN$0
M01 · FY2000 · RR
TREATMENT OF HIV RELATED TUBERCULOSIS USING RIFABUTIN$0
M01 · FY2000 · RR
TREATMENT OF HIV RELATED TUBERCULOSIS USING RIFABUTIN$0
M01 · FY2000 · RR
ITRACONAZOLE IN CYCLODEXTRIN VS PLACEBO IN ASPERGILLOMA$0
M01 · FY2000 · RR
ITRACONAZOLE IN CYCLODEXTRIN VS PLACEBO IN ASPERGILLOMA$0
M01 · FY2000 · RR
ITRACONAZOLE IN CYCLODEXTRIN VS PLACEBO IN ASPERGILLOMA$0
M01 · FY2000 · RR